ATP4B

Summary

ATP4B (ATPase H+/K+ transporting subunit beta, HGNC:820) is a protein-coding gene on chromosome 13q34, encoding Potassium-transporting ATPase subunit beta (P51164). The beta subunit of the gastric H(+)/K(+) ATPase pump which transports H(+) ions in exchange for K(+) ions across the apical membrane of parietal cells.

The protein encoded by this gene belongs to a family of P-type cation-transporting ATPases. The gastric H+, K+-ATPase is a heterodimer consisting of a high molecular weight catalytic alpha subunit and a smaller but heavily glycosylated beta subunit. This enzyme is a proton pump that catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. It is also responsible for gastric acid secretion. This gene encodes the beta subunit of the gastric H+, K+-ATPase.

Source: NCBI Gene 496 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 63 total — 1 pathogenic
• GTEx eGene: eQTL in 4 tissues, sQTL in 0 (q < 0.05)
• Drug target: yes — 11 via a complex or family; 5 molecules with ChEMBL bioactivity
• Approved drugs acting on a complex or family including it: 8 — Dexlansoprazole, Esomeprazole Sodium, Esomeprazole Strontium, +5 more (Potassium-transporting ATPase)
• Constraint (gnomAD): pLI 0.00 (LoF-tolerant), LOEUF 1.04 (unconstrained)
• MANE Select transcript: NM_000705
• Notable: 63 clinical variants but no curated precision-oncology (CIViC) evidence yet

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:820
Approved symbol	ATP4B
Name	ATPase H+/K+ transporting subunit beta
Location	13q34
Locus type	gene with protein product
Status	Approved
Aliases	ATP6B
Ensembl gene	ENSG00000186009
Ensembl biotype	protein_coding
OMIM	137217
Entrez	496

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

MANE Select: ENST00000335288

Transcript support level (Ensembl TSL; 1 = fully mRNA-supported): TSL 1: 1

ENST00000335288

RefSeq mRNA: 1 — MANE Select: NM_000705 NM_000705

CCDS: CCDS9539

Canonical transcript exons

ENST00000335288 — 7 exons

Exon	Start	End
ENSE00001335684	113650406	113650507
ENSE00001335687	113651671	113651727
ENSE00001335690	113652873	113653072
ENSE00001335693	113653321	113653434
ENSE00001335697	113654814	113654942
ENSE00001335698	113648804	113649535
ENSE00001335703	113658033	113658198

Expression profiles

Bgee: expression breadth broad, 93 present calls, max score 88.30.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.2254 / max 410.1016, expressed in 1 samples.

Highest expression (Bgee): body of stomach, stomach, fundus of stomach, uterine tube, fallopian tube.

Genetic regulation across tissues (GTEx eQTL / sQTL)

ATP4B is an eGene in GTEx v10 — its expression is genetically regulated (eQTL) in 4 tissues and its splicing (sQTL) in 0 (q < 0.05). Strongest associations first; slope = normalized effect of the lead variant’s alternative allele.

4 significant tissue × QTL associations:

Tissue	QTL	q-value	Slope	Lead variant
Thyroid	eqtl	6.5e-11	-0.35	13:113648307:G:A
Cells EBV-transformed lymphocytes	eqtl	1.6e-02	+0.24	13:112909711:C:G
Testis	eqtl	2.1e-02	+0.42	13:112932246:C:G
Brain Cerebellum	eqtl	2.6e-02	-0.54	13:113087276:G:A

FANTOM5 promoters

1 alternative TSS:

Promoter ID	TPM avg	Samples expressed
138364	0.2254	1

Top tissues by expression

showing 100 of 121 tissues by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
body of stomach	UBERON:0001161	88.30	gold quality
stomach	UBERON:0000945	87.14	gold quality
fundus of stomach	UBERON:0001160	80.95	gold quality
right uterine tube	UBERON:0001302	73.75	gold quality
fallopian tube	UBERON:0003889	60.32	gold quality
right lobe of thyroid gland	UBERON:0001119	54.32	gold quality
left lobe of thyroid gland	UBERON:0001120	53.96	gold quality
thyroid gland	UBERON:0002046	53.47	gold quality
spleen	UBERON:0002106	52.04	gold quality
adult mammalian kidney	UBERON:0000082	50.62	gold quality
endocervix	UBERON:0000458	48.78	gold quality
hypothalamus	UBERON:0001898	48.72	gold quality
kidney	UBERON:0002113	47.25	gold quality
right lung	UBERON:0002167	46.85	gold quality
cortex of kidney	UBERON:0001225	46.20	gold quality
Ammon’s horn	UBERON:0001954	44.74	gold quality
right coronary artery	UBERON:0001625	44.22	gold quality
right adrenal gland	UBERON:0001233	42.85	gold quality
lower esophagus mucosa	UBERON:0035834	42.81	silver quality
body of pancreas	UBERON:0001150	42.58	gold quality
uterine cervix	UBERON:0000002	42.46	gold quality
left uterine tube	UBERON:0001303	41.72	gold quality
ectocervix	UBERON:0012249	41.45	silver quality
right lobe of liver	UBERON:0001114	41.42	silver quality
temporal lobe	UBERON:0001871	41.40	gold quality
colonic epithelium	UBERON:0000397	41.34	gold quality
amygdala	UBERON:0001876	41.18	gold quality
right adrenal gland cortex	UBERON:0035827	40.89	gold quality
esophagus mucosa	UBERON:0002469	40.49	gold quality
caudate nucleus	UBERON:0001873	39.92	gold quality
urinary bladder	UBERON:0001255	39.69	gold quality
esophagus	UBERON:0001043	39.34	gold quality
left adrenal gland cortex	UBERON:0035825	39.34	gold quality
left adrenal gland	UBERON:0001234	39.21	gold quality
hindlimb stylopod muscle	UBERON:0004252	39.15	gold quality
pituitary gland	UBERON:0000007	39.03	gold quality
transverse colon	UBERON:0001157	38.95	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	38.88	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	38.82	silver quality
descending thoracic aorta	UBERON:0002345	38.74	silver quality
adrenal gland	UBERON:0002369	38.48	gold quality
bone marrow cell	CL:0002092	38.30	gold quality
lower esophagus	UBERON:0013473	38.30	gold quality
lower esophagus muscularis layer	UBERON:0035833	38.30	gold quality
metanephros cortex	UBERON:0010533	38.08	silver quality
right ovary	UBERON:0002118	37.82	silver quality
C1 segment of cervical spinal cord	UBERON:0006469	37.67	gold quality
liver	UBERON:0002107	37.55	silver quality
muscle tissue	UBERON:0002385	37.52	gold quality
pancreas	UBERON:0001264	37.46	gold quality
blood	UBERON:0000178	37.23	gold quality
multicellular organism	UBERON:0000468	37.06	gold quality
thoracic aorta	UBERON:0001515	37.00	gold quality
smooth muscle tissue	UBERON:0001135	36.87	silver quality
ovary	UBERON:0000992	36.86	silver quality
left ovary	UBERON:0002119	36.76	gold quality
ascending aorta	UBERON:0001496	36.72	gold quality
adenohypophysis	UBERON:0002196	36.67	silver quality
body of uterus	UBERON:0009853	36.57	silver quality
colon	UBERON:0001155	36.55	gold quality
ventricular zone	UBERON:0003053	36.48	gold quality
cortical plate	UBERON:0005343	36.47	gold quality
intestine	UBERON:0000160	36.36	gold quality
heart left ventricle	UBERON:0002084	36.23	gold quality
myometrium	UBERON:0001296	36.16	silver quality
gastrocnemius	UBERON:0001388	36.09	gold quality
prostate gland	UBERON:0002367	36.04	gold quality
small intestine	UBERON:0002108	35.98	silver quality
corpus callosum	UBERON:0002336	35.97	gold quality
granulocyte	CL:0000094	35.88	gold quality
mucosa of stomach	UBERON:0001199	35.84	silver quality
small intestine Peyer’s patch	UBERON:0003454	35.81	silver quality
right atrium auricular region	UBERON:0006631	35.80	gold quality
heart	UBERON:0000948	35.75	gold quality
vagina	UBERON:0000996	35.69	gold quality
muscle of leg	UBERON:0001383	35.30	gold quality
left coronary artery	UBERON:0001626	35.29	gold quality
lung	UBERON:0002048	34.98	gold quality
mucosa of transverse colon	UBERON:0004991	34.96	gold quality
brain	UBERON:0000955	34.60	gold quality
upper lobe of left lung	UBERON:0008952	34.29	gold quality
tibial artery	UBERON:0007610	34.24	gold quality
popliteal artery	UBERON:0002250	34.18	gold quality
muscle layer of sigmoid colon	UBERON:0035805	34.01	gold quality
tonsil	UBERON:0002372	33.82	gold quality
minor salivary gland	UBERON:0001830	33.58	gold quality
omental fat pad	UBERON:0010414	33.58	gold quality
saliva-secreting gland	UBERON:0001044	33.48	gold quality
skeletal muscle tissue	UBERON:0001134	33.38	gold quality
substantia nigra	UBERON:0002038	32.95	gold quality
bone marrow	UBERON:0002371	32.83	gold quality
duodenum	UBERON:0002114	32.82	gold quality
adipose tissue	UBERON:0001013	32.72	gold quality
subcutaneous adipose tissue	UBERON:0002190	32.11	gold quality
rectum	UBERON:0001052	32.05	silver quality
endometrium	UBERON:0001295	31.88	gold quality
skin of leg	UBERON:0001511	31.66	gold quality
zone of skin	UBERON:0000014	31.34	gold quality
nucleus accumbens	UBERON:0001882	31.28	gold quality
leukocyte	CL:0000738	31.25	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	1.46

HPA expression

RNA tissue specificity: Tissue enriched

20 HPA tissues / cells by nTPM:

Tissue / cell	Axis	nTPM	Protein (IHC)
Stomach 1	tissue	532.4	high
Choroid plexus	tissue	7.9
Fallopian tube	tissue	3.1	not detected
Kidney	tissue	0.3	not detected
Spinal cord	tissue	0.2
Pituitary gland	tissue	0.1
Cerebral cortex	tissue	0.1	not detected
Colon	tissue	0.1	not detected
Putamen	tissue	0.1
Nucleus accumbens	tissue	0.1
Medulla oblongata	tissue	0.1
Thyroid gland	tissue	0.1	not detected
Spleen	tissue	0.1	not detected
Locus coeruleus	tissue	0.1
Hippocampus	tissue	0.1	not detected
Corpus callosum	tissue	0.1
Prostate	tissue	0.1	not detected
Thymus	tissue	0.1
Postcentral gyrus	tissue	0.1
Retrosplenial cortex	tissue	0.1

Brain sub-regions (HPA Brain Atlas): detected in 150; highest nTPM — Nucleus tractus solitarii (1.4), Periaquaductal grey, lateral (1.3), Cervical spinal cord, central gray (1.2), Dorsal raphe nucleus (0.8), Periaquaductal grey, dorsal (0.7).

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

Targeting ATP4B by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific).

showing 30 of 39 miRNAs:

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-548E-5P	99.89	72.73	4486
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-4447	99.85	67.81	2900
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-7856-5P	99.75	69.99	2901
HSA-MIR-148A-3P	99.74	73.77	1700
HSA-MIR-148B-3P	99.74	73.75	1700
HSA-MIR-152-3P	99.74	73.75	1703
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-3618	99.69	68.57	1012
HSA-MIR-451B	99.55	68.28	1380
HSA-MIR-3616-5P	99.55	67.02	989
HSA-MIR-573	99.55	67.44	955
HSA-MIR-7159-5P	99.53	72.12	2472
HSA-MIR-5007-3P	99.51	68.14	1242
HSA-MIR-548G-3P	99.48	68.67	2159
HSA-MIR-1244	99.33	68.38	832
HSA-MIR-3191-5P	99.24	66.52	1722
HSA-MIR-4477B	99.23	70.49	1733
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-513B-3P	98.76	68.12	1577

Functional genomics

gnomAD constraint: pLI 1.1e-07, LOEUF 1.04, missense Z 0.0798 — population loss-of-function intolerance (pLI ≥ 0.9 = LoF-intolerant; lower LOEUF = more constrained). gnomAD

Regional missense constraint (gnomAD RMC): no regional variation along ENST00000335288 — one region, missense o/e 0.97.

Literature-anchored findings (GeneRIF, showing 5)

• Content of the beta1 subunit of sodium potassium pump in resistance trained control subjects was 33% higher in trained compared to untrained leg, and 47% higher in trained compared to untrained leg in diabetics. (PMID:14685860)
• Thus prolonged exhaustive exercise impaired each of the maximal in vitro Na+-K+-ATPase activity, Ca2+ release, and Ca2+ uptake rates. (PMID:15155714)
• Use of fold recognition methods enables the prediction that a C-terminal domain of the beta subunits of Na,K-ATPase and H,K-ATPase has an immunoglobulin-like fold, which resembles cell adhesion molecules. (PMID:19694409)
• Downregulation of ATP4B gene is associated with gastric cancer. (PMID:23317218)
• these findings demonstrated that a decrease in pHi, caused by H+/K+-ATPase inhibition induced by BMT-1, triggered the dysfunction of the mitochondria resulting in the apoptosis of MM cells (PMID:24700195)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Atp4b	ENSMUSG00000031449
rattus_norvegicus	Atp4b	ENSRNOG00000018543
drosophila_melanogaster	CG33310	FBGN0053310
caenorhabditis_elegans		WBGENE00008074

Paralogs (4): ATP1B3 (ENSG00000069849), ATP1B4 (ENSG00000101892), ATP1B2 (ENSG00000129244), ATP1B1 (ENSG00000143153)

Mouse-model phenotypes

Observed phenotypes of the mouse ortholog (MGI:88114) from MGI (Alliance of Genome Resources) — knockout/mutant phenotypes, ranked by annotation count. 7 distinct phenotype terms.

Mouse phenotype (MP)	Records
abnormal gastric gland morphology	2
abnormal gastric chief cell morphology	2
abnormal gastric parietal cell morphology	1
increased circulating gastrin level	1
increased stomach mucosa thickness	1
increased stomach pH	1
abnormal stomach mucosa morphology	1

Additional cross-species homologs

Sequence homologs in species beyond Ensembl Compara’s model organisms, by Diamond local protein alignment (% sequence identity; best hit per species). Lower-identity rows are more distant homologs. The matched accessions’ gene symbols aren’t in biobtree yet, so each row shows the UniProt accession.

Organism	UniProt	Identity	Method
Ochotona curzoniae	Q5J583	99.7%	Diamond
Oryctolagus cuniculus	Q8WMG3	99.7%	Diamond
Bos taurus	Q28030	98.3%	Diamond
Macaca fascicularis	Q4R4V5	98.3%	Diamond
Sus scrofa	Q9BDK6	96.3%	Diamond
Cavia porcellus	Q9JM72	91.2%	Diamond
Canis lupus familiaris	P33704	84.8%	Diamond
Gallus gallus	P08251	71.4%	Diamond
Anguilla anguilla	Q9I9C3	70.1%	Diamond
Xenopus laevis	P21188	65.7%	Diamond
Rhinella marina	P30716	65.7%	Diamond

Genomic neighbors (locus context)

Genes flanking this one on the chromosome (NCBI/Entrez gene neighborhood). Positional context only — some neighbors share regulatory elements (bidirectional promoters, antisense/overlapping transcripts), but chromosomal adjacency is not itself a functional relationship (see Interactions for that).

Symbol	Type	Entrez
GAS6	protein-coding	2621
TMEM255B	protein-coding	348013
GRK1	protein-coding	6011
GAS6-AS1	ncRNA	650669
TFDP1	protein-coding	7027
LINC00552	ncRNA	100130386
SLC9D1	protein-coding	55002
DCUN1D2	protein-coding	55208
ADPRHL1	protein-coding	113622
GAS6-DT	ncRNA	100506394
LINC00454	ncRNA	100874178

Protein

Protein identifiers

Potassium-transporting ATPase subunit beta — P51164 (reviewed: P51164)

Alternative names: Gastric H(+)/K(+) ATPase subunit beta, Proton pump beta chain

All UniProt accessions (1): P51164

UniProt curated annotations — full annotation on UniProt →

Function. The beta subunit of the gastric H(+)/K(+) ATPase pump which transports H(+) ions in exchange for K(+) ions across the apical membrane of parietal cells. Plays a structural and regulatory role in the assembly and membrane targeting of a functionally active pump. Within a transport cycle, the transfer of a H(+) ion across the membrane is coupled to ATP hydrolysis and is associated with a transient phosphorylation of the alpha subunit that shifts the pump conformation from inward-facing (E1) to outward-facing state (E2). Interacts with the phosphorylation domain of the alpha subunit and functions as a ratchet, stabilizing the lumenal-open E2 conformation and preventing the reverse reaction of the transport cycle.

Subunit / interactions. The ATPase pump is composed of two subunits: alpha (catalytic) and beta (regulatory). Interacts with alpha subunit ATP12A; this interaction is required for the formation of a functionally active pump and targeting at the plasma membrane. Interacts (via N-terminus) with alpha subunit ATP4A (via the P-domain).

Subcellular location. Apical cell membrane. Cell membrane.

Post-translational modifications. N-glycosylation is necessary for assembly and functional expression of the pump at the plasma membrane.

Domain organisation. The C-terminal lobe folds into an immunoglobulin-like domain and mediates cell adhesion properties.

Similarity. Belongs to the X(+)/potassium ATPases subunit beta family.

RefSeq proteins (1): NP_000696* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000402	Na/K_ATPase_sub_beta	Family
IPR038702	Na/K_ATPase_sub_beta_sf	Homologous_superfamily

Pfam: PF00287

UniProt features (15 total): glycosylation site 7, disulfide bond 3, topological domain 2, chain 1, transmembrane region 1, region of interest 1

Structure

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P51164-F1	90.68	0.76

Human Protein Atlas

Protein class: Metabolic proteins, Transporters, Primary Active Transporters, Predicted membrane proteins, FDA approved drug targets, Small molecule drugs

Protein evidence: Evidence at protein level

Subcellular location (HPA, imaging): plasma membrane

Antibody reliability (HPA): IH enhanced · IF approved

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (3)

Type	Positions
Disulfide bond	131–152, 162–178, 201–263

Glycosylation sites (7)

Type	Positions
N-linked (glcnac…) asparagine	193, 222, 99, 103, 130, 146, 161

Function

Pathways and Gene Ontology

Reactome pathways

1 curated (TAS) of 3; 0 disease pathways. Curated-first; evidence = TAS (manually curated) vs IEA (electronic inference).

3 pathways:

ID	Pathway	Evidence
R-HSA-936837	Ion transport by P-type ATPases	curated
R-HSA-983712	Ion channel transport	—
R-HSA-382551	Transport of small molecules	—

MSigDB gene sets: 131 (showing top): GOBP_POTASSIUM_ION_TRANSPORT, GOBP_SODIUM_ION_TRANSMEMBRANE_TRANSPORT, GOBP_POTASSIUM_ION_HOMEOSTASIS, MORF_RAD51L3, GOBP_MONOATOMIC_CATION_TRANSPORT, MORF_CTSB, chr13q34, MORF_IL4, GOBP_INTRACELLULAR_POTASSIUM_ION_HOMEOSTASIS, MORF_PRKCA, GOBP_INTRACELLULAR_SODIUM_ION_HOMEOSTASIS, GOBP_RESPONSE_TO_OXYGEN_CONTAINING_COMPOUND, GOBP_SODIUM_ION_HOMEOSTASIS, GOBP_RESPONSE_TO_LIPID, GOMF_PROTON_TRANSMEMBRANE_TRANSPORTER_ACTIVITY

GO Biological Process (11): intracellular sodium ion homeostasis (GO:0006883), cell adhesion (GO:0007155), intracellular potassium ion homeostasis (GO:0030007), response to lipopolysaccharide (GO:0032496), sodium ion export across plasma membrane (GO:0036376), pH reduction (GO:0045851), potassium ion import across plasma membrane (GO:1990573), monoatomic ion transport (GO:0006811), potassium ion transport (GO:0006813), sodium ion transport (GO:0006814), proton transmembrane transport (GO:1902600)

GO Molecular Function (4): ATPase activator activity (GO:0001671), P-type potassium:proton transporter activity (GO:0008900), heterocyclic compound binding (GO:1901363), protein binding (GO:0005515)

GO Cellular Component (3): plasma membrane (GO:0005886), sodium:potassium-exchanging ATPase complex (GO:0005890), apical plasma membrane (GO:0016324)

Reactome top-level categories

2 top-level categories:

Category	Pathways
Ion channel transport	1
Transport of small molecules	1

GO top-level categories

27 GO namespaces:

Category	Terms
intracellular monoatomic cation homeostasis	2
metal ion transport	2
sodium ion homeostasis	1
cellular process	1
potassium ion homeostasis	1
response to molecule of bacterial origin	1
response to lipid	1
response to oxygen-containing compound	1
sodium ion transmembrane transport	1
export across plasma membrane	1
regulation of pH	1
potassium ion transmembrane transport	1
inorganic cation import across plasma membrane	1
transport	1
monoatomic cation transmembrane transport	1
ATP-dependent activity	1
molecular function activator activity	1
P-type proton-exporting transporter activity	1
P-type potassium transmembrane transporter activity	1
small molecule binding	1
binding	1
membrane	1
cell periphery	1
cation-transporting ATPase complex	1
plasma membrane protein complex	1
apical part of cell	1
plasma membrane region	1

Protein interactions and networks

STRING

showing 15 of 708 interactions by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ATP4B	ATP12A	P54707	764
ATP4B	ATP4A	P20648	717
ATP4B	ATP7B	P35670	674
ATP4B	CBLIF	P27352	668
ATP4B	DNAH8	Q96JB1	615
ATP4B	PGC	P20142	564
ATP4B	CLTC	Q00610	552
ATP4B	GRTP1	Q5TC63	532
ATP4B	SLC9D1	Q6UWJ1	522
ATP4B	TFF2	Q03403	518
ATP4B	PGA4	P00790	497
ATP4B	PGA4	P00790	490
ATP4B	GAST	P01350	485
ATP4B	GKN1	Q9NS71	470
ATP4B	WFDC8	Q8IUA0	469

IntAct

Human interaction partners of ATP4B in IntAct, one row per partner (best MIscore; records = supporting IntAct interaction records).

6 partners by confidence:

Partner	Interaction type	MIscore	Records
CCNDBP1	physical association	0.560	3
GPR42	physical association	0.560	3
ZC4H2	physical association	0.560	3
CCT7	physical association	0.400	1
AGO3	physical association	0.370	1
BPGM	physical association	0.370	1

BioGRID (7 interactions; top human partners by supporting records): CCNDBP1 (Two-hybrid; 2 records), AGO3 (Two-hybrid), ATP4A (Affinity Capture-MS), BPGM (Two-hybrid), GPR42 (Two-hybrid), ZC4H2 (Two-hybrid)

Protein complexes (CORUM) (1)

Experimentally-characterized complexes this protein is a subunit of (★ = the complex contains a known drug target).

1 complexes by size:

Complex	Subunits	Members
★ ATP4A-ATP4B complex	2	ATP4A, ATP4B

Disease & clinical

Genetic variants

Variant evidence for ATP4B: 63 ClinVar records (1 pathogenic / likely pathogenic); 1 GWAS association. Per-variant detail is on Sugi Variant.

ClinVar

63 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	52
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (1)

Showing all 1 pathogenic / likely-pathogenic ClinVar records, ranked by ClinVar review status (expert panel → multiple submitters → single submitter), then by number of submitting labs.

Variant ID	HGVS	Classification	Review	Submitters
4279224	GRCh37/hg19 13q33.1-34(chr13:104324715-115107733)x1	Pathogenic	criteria provided, single submitter	1

Per-variant reference — Sugi Variant

Explore ATP4B’s pathogenic and likely-pathogenic variants individually — each with its ClinVar classification and conditions, applied ACMG criteria (ClinGen expert panel, where curated), the calibrated in-silico predictors (AlphaMissense, REVEL, SaProt, conservation), gnomAD frequency, and the predictor-disagreement QC signal — on Sugi Variant.

SpliceAI

Top 10 splice-impact sites by Δscore (adjacent positions with the same effect merged into one range; 32 predictions of 872):

Position(s)	Effect	Δscore	Sites
13:113649536–113649537	acceptor_loss	1.0000	6
13:113649541	acceptor_gain	1.0000
13:113650404–113650405	donor_loss	1.0000	5
13:113652903	donor_gain	1.0000
13:113653834	donor_gain	1.0000
13:113653894	donor_gain	1.0000
13:113654812–113654813	donor_loss	1.0000	4
13:113654943–113654944	acceptor_loss	1.0000	6
13:113654947	acceptor_gain	1.0000
13:113650508–113650509	acceptor_loss	0.9900	6

AlphaMissense

676 missense substitutions predicted likely pathogenic (of 1,927 scored), across 174 residues. Top 20 hotspot residues, ranked by the number of likely-pathogenic substitutions (of those reachable by a single-nucleotide change), then by mean score:

Residue	Likely-pathogenic substitutions	Mean am_pathogenicity	Max am_pathogenicity
N184	8	0.975	0.995
F154	8	0.939	0.997
F285	8	0.938	0.997
D277	8	0.919	0.976
F47	8	0.861	0.970
F55	8	0.822	0.957
D75	8	0.799	0.888
C152	7	0.995	0.998
C263	7	0.995	0.999
C162	7	0.990	0.994
C178	7	0.990	0.993
C201	7	0.989	0.996
F230	7	0.985	0.995
C131	7	0.983	0.993
F170	7	0.977	0.992
F172	7	0.968	0.991
F189	7	0.964	0.984
R185	7	0.939	0.992
W37	7	0.929	0.992
F116	7	0.894	0.961

HPA cancer prognostics

RNA cancer specificity: Cancer enriched (Stomach Adenocarcinoma)

Disease associations

OMIM: gene MIM:137217 | disease phenotypes:

GWAS associations

1 associations:

Study	Trait	p-value
GCST008839_311	Height	1e-10

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL2095173 (PROTEIN COMPLEX)

Drugs acting on a complex or family that includes this protein

Curated ChEMBL mechanism-of-action drugs whose target is a protein complex or family of ≤10 members that includes ATP4B — the drug acts on the assembly or class, not necessarily on this subunit alone.

11 drugs via a complex or family:

Drug	Target (ChEMBL)	Members	Max phase
DEXLANSOPRAZOLE	Potassium-transporting ATPase	2	4
ESOMEPRAZOLE SODIUM	Potassium-transporting ATPase	2	4
ESOMEPRAZOLE STRONTIUM	Potassium-transporting ATPase	2	4
LANSOPRAZOLE	Potassium-transporting ATPase	2	4
OMEPRAZOLE	Potassium-transporting ATPase	2	4
PANTOPRAZOLE SODIUM	Potassium-transporting ATPase	2	4
RABEPRAZOLE SODIUM	Potassium-transporting ATPase	2	4
VONOPRAZAN FUMARATE	Potassium-transporting ATPase	2	4
ABEPRAZAN	Potassium-transporting ATPase	2	3
ILAPRAZOLE	Potassium-transporting ATPase	2	3
TEGOPRAZAN	Potassium-transporting ATPase	2	3

Molecules with ChEMBL bioactivity

Phase ≥1, by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 170,396 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

5 molecules by phase:

Molecule	Name	Phase	Patents
CHEMBL30	CIMETIDINE	4	47,592
CHEMBL480	LANSOPRAZOLE	4	24,499
CHEMBL1503	OMEPRAZOLE	4	52,666
CHEMBL1502	PANTOPRAZOLE	4	14,827
CHEMBL1790041	RANITIDINE	4	30,812

PharmGKB: 1 entry (CPIC guideline: no)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — H⁺/K⁺-ATPases

Binding affinities (BindingDB)

244 measured of 262 human assays (262 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
CHEMBL1202672	IC50	20 nM
CHEMBL1202647	IC50	50 nM
(+/-)-(2-Methyl-8-phenyl-7,8-dihydro-6H-9-oxa-1,3a-diaza-cyclopenta[a]naphthalen-3-yl)-acetonitrile	IC50	64 nM
CHEMBL1202621	IC50	110 nM
CHEMBL1202658	IC50	110 nM
CHEMBL1202663	IC50	120 nM
CHEMBL1202681	IC50	120 nM
CHEMBL1202667	IC50	120 nM
CHEMBL1202661	IC50	120 nM
(2-Methyl-8-phenethyl-imidazo[1,2-a]pyridin-3-yl)-acetonitrile	IC50	130 nM
CHEMBL1202659	IC50	130 nM
CHEMBL1202656	IC50	140 nM
CHEMBL1202607	IC50	140 nM
CHEMBL1202651	IC50	150 nM
CHEMBL1202654	IC50	150 nM
CHEMBL1202629	IC50	160 nM
CHEMBL1202671	IC50	170 nM
CHEMBL1202678	IC50	170 nM
CHEMBL1202660	IC50	180 nM
CHEMBL1202679	IC50	180 nM
CHEMBL1202668	IC50	180 nM
CHEMBL1202655	IC50	180 nM
2-(1H-Benzoimidazole-2-sulfinylmethyl)-4-methoxy-3,5-dimethyl-phenylamine	IC50	200 nM
CHEMBL1202666	IC50	200 nM
CHEMBL1202677	IC50	220 nM
CHEMBL1202673	IC50	230 nM
CHEMBL1202642	IC50	230 nM
CHEMBL1202615	IC50	230 nM
CHEMBL1202675	IC50	240 nM
CHEMBL1202643	IC50	250 nM
CHEMBL1202638	IC50	250 nM
CHEMBL1202608	IC50	250 nM
CHEMBL1202648	IC50	260 nM
CHEMBL1202669	IC50	260 nM
CHEMBL1202644	IC50	260 nM
CHEMBL1202670	IC50	260 nM
CHEMBL1202649	IC50	270 nM
CHEMBL1202645	IC50	290 nM
CHEMBL1203503	IC50	300 nM
8-Benzyloxy-2-methyl-imidazo[1,2-a]pyridin-3-ylamine	IC50	310 nM
CHEMBL1202653	IC50	310 nM
CHEMBL1202665	IC50	310 nM
CHEMBL1202646	IC50	320 nM
CHEMBL1202614	IC50	370 nM
CHEMBL1202682	IC50	390 nM
CHEMBL9585	IC50	398 nM
Dibutyl-(3-{4-[2-(5-chloro-benzothiazol-2-yl)-vinyl]-phenoxy}-propyl)-amine;hydrochloride	IC50	400 nM
2-(2,4-Diethoxy-phenylmethanesulfinyl)-N-pyridin-4-yl-nicotinamide	IC50	400 nM
CHEMBL1202683	IC50	420 nM
CHEMBL1202640	IC50	430 nM

ChEMBL bioactivities

249 potent at pChembl≥5 of 306 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
7.70	IC50	20	nM	CHEMBL1202672
7.52	IC50	30	nM	CHEMBL1202661
7.40	IC50	40	nM	RANITIDINE
7.30	IC50	50	nM	CHEMBL1202647
7.30	IC50	50	nM	CHEMBL1202621
7.19	IC50	64	nM	CHEMBL296482
7.19	IC50	65	nM	CHEMBL47529
7.10	IC50	80	nM	CHEMBL1202681
7.10	IC50	80	nM	CHEMBL1202672
7.10	IC50	80	nM	CHEMBL1202647
7.05	IC50	90	nM	CHEMBL1202667
6.96	IC50	110	nM	CHEMBL1202658
6.96	IC50	110	nM	CHEMBL1202621
6.92	IC50	120	nM	CHEMBL1202681
6.92	IC50	120	nM	CHEMBL1202661
6.92	IC50	120	nM	CHEMBL1202663
6.92	IC50	120	nM	CHEMBL1202667
6.89	IC50	130	nM	CHEMBL1202663
6.89	IC50	130	nM	CHEMBL1202659
6.89	IC50	130	nM	CHEMBL293244
6.85	IC50	140	nM	CHEMBL1202607
6.85	IC50	140	nM	CHEMBL1202656
6.82	IC50	150	nM	CHEMBL1202651
6.82	IC50	150	nM	CHEMBL1202654
6.80	IC50	160	nM	CHEMBL1202629
6.77	IC50	170	nM	CHEMBL1202678
6.77	IC50	170	nM	CHEMBL1202671
6.75	IC50	180	nM	CHEMBL1202660
6.75	IC50	180	nM	CHEMBL1202679
6.75	IC50	180	nM	CHEMBL1202655
6.75	IC50	180	nM	CHEMBL1202668
6.70	IC50	200	nM	CHEMBL1202666
6.70	IC50	200	nM	CHEMBL20162
6.68	IC50	210	nM	CHEMBL1202607
6.68	IC50	210	nM	CHEMBL1202655
6.68	IC50	210	nM	CHEMBL1202656
6.66	IC50	220	nM	CHEMBL1202677
6.64	IC50	230	nM	CHEMBL1202642
6.64	IC50	230	nM	CHEMBL1202615
6.64	IC50	230	nM	CHEMBL1202668
6.64	IC50	230	nM	CHEMBL1202673
6.62	IC50	240	nM	CHEMBL1202675
6.62	IC50	240	nM	CHEMBL1202678
6.60	IC50	250	nM	OMEPRAZOLE
6.60	IC50	250	nM	CHEMBL1202643
6.60	IC50	250	nM	CHEMBL1202608
6.60	IC50	250	nM	CHEMBL1202638
6.58	IC50	260	nM	CHEMBL1202666
6.58	IC50	260	nM	CHEMBL1202643
6.58	IC50	260	nM	CHEMBL1202644

PubChem BioAssay actives

251 with measured affinity, of 493 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
4-[4-(3-imidazol-1-ylpropoxy)phenyl]-2-phenyl-1,3-thiazole;hydrate;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.0200	uM
4-[4-[(E)-2-(1,3-benzothiazol-2-yl)ethenyl]phenoxy]-N,N-dipropylbutan-1-amine;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.0300	uM
1-N’-[2-[[5-[(dimethylamino)methyl]furan-2-yl]methylsulfanyl]ethyl]-1-N-methyl-2-nitroethene-1,1-diamine	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.0400	uM
2-phenyl-4-[4-(3-piperidin-1-ylpropoxy)phenyl]-1,3-thiazole;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.0500	uM
N-butyl-N-[3-[4-[(E)-2-(6-methoxy-1,3-benzoxazol-2-yl)ethenyl]phenoxy]propyl]butan-1-amine;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.0500	uM
2-(4-methyl-12-phenyl-13-oxa-3,6-diazatricyclo[7.4.0.02,6]trideca-1(9),2,4,7-tetraen-5-yl)acetonitrile	78910: Inhibition of H+/K+ ATPase as reduced acid formation in rabbit gastric glands	ic50	0.0640	uM
2-(2-methyl-8-phenylmethoxyimidazo[1,2-a]pyridin-3-yl)acetonitrile	78910: Inhibition of H+/K+ ATPase as reduced acid formation in rabbit gastric glands	ic50	0.0650	uM
4-[4-[(E)-2-(1,3-benzoxazol-2-yl)ethenyl]phenoxy]-N,N-diethylbutan-1-amine;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.0800	uM
N,N-diethyl-3-[4-(2-phenyl-1,3-thiazol-4-yl)phenoxy]propan-1-amine;hydrate;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.0900	uM
4-[4-[(E)-2-(1,3-benzoxazol-2-yl)ethenyl]phenoxy]-N,N-dipropylbutan-1-amine;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.1100	uM
N,N-dibutyl-4-[4-(2-phenyl-1,3-thiazol-4-yl)phenoxy]butan-1-amine;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.1200	uM
2-[2-methyl-8-(2-phenylethyl)imidazo[1,2-a]pyridin-3-yl]acetonitrile	78910: Inhibition of H+/K+ ATPase as reduced acid formation in rabbit gastric glands	ic50	0.1300	uM
2-[(E)-2-[4-(3-imidazol-1-ylpropoxy)phenyl]ethenyl]-1,3-benzothiazole;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.1300	uM
3-[4-[(E)-2-(1,3-benzothiazol-2-yl)ethenyl]phenoxy]-N,N-dipropylpropan-1-amine;hydrate;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.1400	uM
3-[4-(1,3-benzothiazol-2-yl)phenoxy]-N,N-dipropylpropan-1-amine;hydrate;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.1400	uM
N-[3-[4-[(E)-2-(1,3-benzoxazol-2-yl)ethenyl]phenoxy]propyl]-N-butylbutan-1-amine;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.1500	uM
3-[4-[(E)-2-(1,3-benzothiazol-2-yl)ethenyl]phenoxy]-N,N-diethylpropan-1-amine;hydrate;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.1500	uM
2-[(E)-2-[4-(4-pyrrolidin-1-ylbutoxy)phenyl]ethenyl]-1,3-benzothiazole;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.1600	uM
2-[(E)-2-[4-(4-piperidin-1-ylbutoxy)phenyl]ethenyl]-1,3-benzoxazole;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.1700	uM
2-[(E)-2-[4-(4-pyrrolidin-1-ylbutoxy)phenyl]ethenyl]-1,3-benzoxazole;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.1700	uM
2-[(E)-2-[4-(3-piperidin-1-ylpropoxy)phenyl]ethenyl]-1,3-benzothiazole;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.1800	uM
4-[4-[(E)-2-(1,3-benzothiazol-2-yl)ethenyl]phenoxy]-N,N-diethylbutan-1-amine;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.1800	uM
3-[4-(2-phenyl-1,3-thiazol-4-yl)phenoxy]-N,N-dipropylpropan-1-amine;hydrate;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.1800	uM
4-[4-[(E)-2-(1,3-benzoxazol-2-yl)ethenyl]phenoxy]-N,N-dibutylbutan-1-amine;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.1800	uM
2-(1H-benzimidazol-2-ylsulfinylmethyl)-4-methoxy-3,5-dimethylaniline	78730: In vitro inhibitory activity against H+/K+ ATPase prepared from canine fundic mucosa	ic50	0.2000	uM
2-[(E)-2-[4-(4-imidazol-1-ylbutoxy)phenyl]ethenyl]-1,3-benzothiazole;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.2000	uM
3-[4-[(E)-2-(1,3-benzoxazol-2-yl)ethenyl]phenoxy]-N,N-dipropylpropan-1-amine;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.2200	uM
2-[(E)-2-[4-(5-imidazol-1-ylpentoxy)phenyl]ethenyl]-1,3-benzoxazole;hydrate;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.2300	uM
N-butyl-N-[3-[4-[2-(4-methoxyphenyl)-1,3-thiazol-4-yl]phenoxy]propyl]butan-1-amine;hydrate;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.2300	uM
N-butyl-N-[3-[4-(5-methyl-2-phenyl-1,3-thiazol-4-yl)phenoxy]propyl]butan-1-amine;hydrate;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.2300	uM
N-butyl-N-[3-[4-(5-ethyl-2-phenyl-1,3-thiazol-4-yl)phenoxy]propyl]butan-1-amine;hydrate;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.2400	uM
6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.2500	uM
2-[(E)-2-[4-(3-imidazol-1-ylpropoxy)phenyl]ethenyl]-1,3-benzoxazole;hydrate;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.2500	uM
N-[3-[4-(1,3-benzothiazol-2-yl)phenoxy]propyl]-N-butylbutan-1-amine;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.2500	uM
N-[3-[4-[(E)-2-(1,3-benzothiazol-2-yl)ethenyl]phenoxy]propyl]-N-butylbutan-1-amine;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.2500	uM
N-[2-[4-[(E)-2-(1,3-benzoxazol-2-yl)ethenyl]phenoxy]ethyl]-N-butylbutan-1-amine;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.2600	uM
N-butyl-N-[3-[4-[(E)-2-(5-methyl-1,3-benzoxazol-2-yl)ethenyl]phenoxy]propyl]butan-1-amine;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.2600	uM
N-butyl-N-[3-[4-[(E)-2-(6-methoxy-1,3-benzothiazol-2-yl)ethenyl]phenoxy]propyl]butan-1-amine;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.2600	uM
N-butyl-N-[3-[4-[2-(3,5-dimethoxyphenyl)-1,3-thiazol-4-yl]phenoxy]propyl]butan-1-amine;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.2600	uM
2-[(E)-2-[4-(4-imidazol-1-ylbutoxy)phenyl]ethenyl]-1,3-benzoxazole;hydrate;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.2700	uM
N-butyl-N-[3-[4-[(E)-2-(5-methyl-1,3-benzothiazol-2-yl)ethenyl]phenoxy]propyl]butan-1-amine;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.2900	uM
2-benzyl-1-[4-(3,4-dihydroxyphenyl)-1,3-thiazol-2-yl]guanidine;hydrochloride	78732: Inhibitory activity against dog gastric proton-pump enzyme H+/K+ ATPase	ic50	0.3000	uM
2-methyl-8-phenylmethoxyimidazo[1,2-a]pyridin-3-amine	78910: Inhibition of H+/K+ ATPase as reduced acid formation in rabbit gastric glands	ic50	0.3100	uM
N-butyl-N-[2-[4-(2-phenyl-1,3-thiazol-4-yl)phenoxy]ethyl]butan-1-amine;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.3100	uM
4-[4-(4-imidazol-1-ylbutoxy)phenyl]-2-phenyl-1,3-thiazole;hydrate;hydrochloride	167650: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by dibutyryl cyclic adenosine 3’, 5’ -monophosphate (dcAMP)	ic50	0.3100	uM
3-[4-[(E)-2-(1,3-benzoxazol-2-yl)ethenyl]phenoxy]-N,N-diethylpropan-1-amine;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.3200	uM
4-[4-(3-imidazol-1-ylpropoxy)phenyl]-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.3700	uM
2-phenyl-4-[4-(3-pyrrolidin-1-ylpropoxy)phenyl]-1,3-thiazole;hydrochloride	167652: Antisecretory activity evaluated by the inhibition of 14C -AP uptake in isolated rabbit parietal cells stimulated by exogenous histamine	ic50	0.3900	uM
2-[(4-methoxy-3-methyl-2-pyridinyl)methylsulfinyl]-6-(1,1,2,2-tetrafluoroethoxy)-1H-benzimidazole	78913: In vitro evaluation for the inhibition of H+/K+ ATPase at pH < 3 in the gastric glands of isolated rabbit stomach.	ic50	0.3981	uM
Lansoprazole	78913: In vitro evaluation for the inhibition of H+/K+ ATPase at pH < 3 in the gastric glands of isolated rabbit stomach.	ic50	0.3981	uM

CTD chemical–gene interactions

12 total (human), top 12 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	increases expression	1
aflatoxin B2	decreases methylation	1
Sch 28080	affects cotreatment, decreases reaction, increases uptake	1
Resveratrol	affects cotreatment, decreases expression	1
Benzo(a)pyrene	affects methylation	1
Carmustine	decreases expression	1
Diazinon	increases methylation	1
Formaldehyde	decreases expression	1
Ouabain	affects cotreatment, decreases reaction, increases uptake	1
Plant Extracts	affects cotreatment, decreases expression	1
Rubidium	decreases reaction, affects cotreatment, increases uptake	1
Valproic Acid	increases methylation	1

ChEMBL screening assays

17 unique, capped per target: 13 binding, 4 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL686427	Binding	Inhibitory activity against dog gastric proton-pump enzyme H+/K+ ATPase	Antiulcer agents. 4-substituted 2-guanidinothiazoles: reversible, competitive, and selective inhibitors of gastric H+,K(+)-ATPase. — *J Med Chem*
CHEMBL765030	Functional	Inhibition of [14C]aminopyrine (AP) accumulation stimulated by dibutyryl cyclic AMP in isolated rabbit parietal cells	Nicotinamide derivatives as a new class of gastric H+/K(+)-ATPase inhibitors. 1. Synthesis and structure-activity relationships of N-substituted 2-(benzhydryl- and benzylsulfinyl)nicotinamides. — *J Med Chem*

Clinical trials (associated diseases)

Via MONDO — disease-level, not drug-specific.

Predicted chemistry — Sugi Predict

The predicted patent-compound landscape for ATP4B across ~30M SureChEMBL compounds — explore on Sugi Predict.